Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients

P. van Paassen, D. Pittrow, C. Scheidegger, J. Klotsche, P.M. Ellerbroek

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)131-139
Number of pages9
JournalImmunotherapy
Volume12
Issue number2
DOIs
Publication statusPublished - 1 Feb 2020

Keywords

  • deficiency
  • efficacy
  • elderly patients
  • fscig
  • home infusion
  • hyqvia (r)
  • immunodeficiencies
  • infusion
  • management
  • primary immunodeficiencies
  • quality-of-life
  • rates
  • real-world study
  • recombinant human hyaluronidase-facilitated subcutaneous 10% immunoglobulin secondary immunodeficiencies
  • safety
  • therapy
  • EFFICACY
  • SAFETY
  • INFUSION
  • fSCIG
  • RATES
  • THERAPY
  • QUALITY-OF-LIFE
  • HyQvia (R)
  • MANAGEMENT
  • IMMUNODEFICIENCIES
  • DEFICIENCY

Cite this